Clinical trials: neoadjuvant therapy, completed
Melanoma
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of…
- Trial name
- NCT02339324
- Testing
- Pembrolizumab and high dose interferon alfa-2b (HDI)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Yana Najjar
Cutaneous Melanoma, Non-small Cell Lung Cancer
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma
- Trial name
- NCT03633110
- Testing
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genocea Biosciences, Inc.
Cancer of Cervix
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
The propose of this study is to determine if neoadjuvant chemotherapy followed by chemoradiation is safe and effective in locally advanced cervical cancer patients.
- Trial name
- NCT02309658
- Testing
- gemcitabine, cisplatin, chemoradiation
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Squamous Cell Carcinoma
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a randomized multicenter open label phase III factorial trial evaluating the 3 years OS in patients with locally advanced squamous cell carcinoma of head and neck treated with locoregional treatment (radiotherapy plus…
- Trial name
- H&N07 (NCT01086826)
- Testing
- RT+CDDP/5-FU, RT+CETUXIMAB, INDUCTION CTx(TPF)+(RT+CDDP/5-FU)
- Where
- 60 sites in Italy
- Volunteers
- 320 people
- Sponsor
- Associazione Volontari Pazienti Oncologici
Esophageal Neoplasms
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
The purpose of this study is to compare the results of preoperative chemotherapy and radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation for esophageal cancer.
- Trial name
- QUINTETT (NCT00907543)
- Testing
- Preoperative treatment of chemotherapy and radiation, Postoperative treatment of chemotherapy and radiation
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- Richard Malthaner
Locally Advanced Gastric Carcinoma
Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell
Background Local advanced gastric carcinoma (LAGC) is suggested to be potentially cured by R0 resection, and neoadjuvant chemotherapy can increase the R0 resection rate but not enough.
- Trial name
- NCT02048540
- Testing
- Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Mantle Cell Lymphoma
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion.
- Trial name
- PrE0405 (NCT03834688)
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- PrECOG, LLC.
Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment.
- Trial name
- NCT02997761
- Testing
- Blinatumomab, Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of California, Davis
Locally Advanced Rectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer
- Trial name
- NCT03443661
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Aiping Zhou
Esophageal Cancer, Chemoradiation
Organ Motion and Early Tumor Response Measurement
To quantify motion based variation of the target volume of the primary tumor over the course of chemoradiotherapy in esophageal cancer patients, and to use this information to calculate appropriate PTV (planning target volume)…
- Trial name
- NCT02139488
- Testing
- Fiducial markers, Fiducial markers, Pet and MRI
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Colon Cancer
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).
- Trial name
- RESET-C (NCT05662527)
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Camilla Qvortrup
Esophageal Squamous Cell Carcinoma, Efficacy
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity
- Trial name
- NCT06281886
- Testing
- Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00004103
- Testing
- cisplatin, floxuridine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health
Lung Cancer
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC.
- Trial name
- NCT00193427
- Testing
- Docetaxel, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- SCRI Development Innovations, LLC
Triple Negative Breast Cancer Patients
Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen
This is a single arm, single center, non-randomized, phase II trial of stage IIB/III TNBC. Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500…
- Trial name
- CAPneo (NCT03304756)
- Testing
- CAP
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Breast Cancer
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the…
- Trial name
- NCT02956473
- Testing
- Supine MRI, Neoadjuvant Therapy (NAT), Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Triple Negative Breast Cancer
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NECTAR (NCT01931163)
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jenny C. Chang, MD
Early Primary Breast Cancer
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with…
- Trial name
- NCT02214381
- Testing
- Myocet, Cyclophosphamide, Paclitaxel
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Women's Cancer Study Group GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.